IFNG and melanoma: Importantly, the same signature applied to pre-treatment transcriptomic data from patients with melanoma who subsequently received ICIs, consistently out-performed all other candidate predictive biomarkers tested, including PD-L1 levels, tumor mutational burden, and an IFNγ signature (33).